All these tittle tattle about Medusa is a smoke screen. Whilst I get the concerns, B2C sales are some way away and also not what is going to kickstart the SP into overdrive - a couple of sizeable government orders (UK/US and or elsewhere) is what we need and no doubt what initial sales strategy is geared towards.
Another week gone with no tangible update....totally get the process is incredibly complex and they’re essentially trying to cram years worth of work and science into a condensed timeline but the mind does start to boggle given the expectation for, and current lack of news...
Totally agree, nail on head. Short term value is all locked up in Covid testing. LTH's hear for cancer treatment but most current market sentiment banking on them delivering the testing play.
SP will continue to stall until real product news is forthcoming and revenues are imminent. That with media switching off from covid and the Majority thinking we are through the worst makes covid stocks less attractive. I get Avacta is more than a covid play but that’s the reality.